Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Chugai, Taisho To Seek Approval For Co-Developed Drug

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical and Taisho Pharmaceutical, both of Japan, plan to submit their eledecalcitol drug for approval in the country. Phase III trials of the vitamin D derivative have been positive, besting a Teijin competitor in comparison trials for treating fractures related to osteoporosis. Chugai, majority-owned by Roche, discovered the drug and is considering foreign trials, according to a spokesman. (Click here for more

You may also be interested in...



Chugai To Deploy Chiome’s MAb Generation Technology

TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9

QUOTED. 8 July 2020. Stephen Hahn.

BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.

Regeneron COVID-19 Therapeutic, Innovax Vaccine Get BARDA Funding To Boost Manufacturing

US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel